Patents by Inventor Hamish John Allen

Hamish John Allen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020156094
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.
    Type: Application
    Filed: September 25, 2001
    Publication date: October 24, 2002
    Applicant: Warner-Lambert Company
    Inventors: Hans P. Albrecht, Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Catherine Rose Kostlan, Bruce David Roth, Nigel Walker
  • Publication number: 20020099169
    Abstract: It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF&kgr;B, and thus as a modulator of inflammatory responses in which p105 is involved, and as a target for the development of compounds capable of influencing NF&kgr;B activation.
    Type: Application
    Filed: August 13, 1999
    Publication date: July 25, 2002
    Applicant: BASF AKTIENGESELLCHAFT
    Inventors: HAMISH JOHN ALLEN, RICHARD WOODWARD DIXON, JOANNE SARA KAMENS, DINELI WICKRAMASINGHE, YAJUN XU, MONICA POLIDORO BELICH, LELAND HERRIES JOHNSTON, STEVEN CHARLES LEY, ANDRES SALMERON
  • Patent number: 6316415
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: November 13, 2001
    Assignees: BASF Aktiengesellschaft, Warner-Lambert Company
    Inventors: Hans P. Albrecht, Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Catherine Rose Kostlan, Bruce David Roth, Nigel Walker
  • Patent number: 6083981
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula I, II, or III. ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Elizabeth Ann Lunney, Mark Stephen Plummer, Tomi Sawyer, Aurash Shahripour, Nigel Walker
  • Patent number: 5932549
    Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: August 3, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellschaft
    Inventors: Hamish John Allen, Subhashis Banerjee, Kenneth Dale Brady, John Cooke Hodges, Catherine Rose Kostlan, Robert Vincent Talanian
  • Patent number: 5919790
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 6, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellsschaft
    Inventors: Hamish John Allen, Kenneth Dale Brady, Bradley William Caprathe, Paul Galatsis, John Lodge Gilmore, Sheryl Jeanne Hays, Robert Vincent Talanian, Nigel Walker, Joseph Scott Warmus
  • Patent number: 5744451
    Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: April 28, 1998
    Assignees: Warner-Lambert Company, BASF A.G.
    Inventors: Hamish John Allen, Subhashis Banerjee, Kenneth Dale Brady, John Cooke Hodges, Catherine Rose Kostlan, Robert Vincent Talanian